Essex Property Trust vs UDR
ESS and UDR side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ESS and UDR compare
Essex Property Trust is the larger company, worth 1.5 times as much as UDR ($17.0B against $11.4B).
On earnings, UDR is cheaper: it trades at 22.6× trailing earnings, against 41.1× for Essex Property Trust.
Essex Property Trust grew revenue faster over the last twelve months (4.7% versus 1.5% for UDR).
Both pay dividends: Essex Property Trust yields 3.9% and UDR 4.1%.
UDR scores higher on the StockData Score (15 against 6 for Essex Property Trust), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ESS | UDR |
|---|---|---|
| Size and price | ||
| Market cap | $17.0B | $11.4B |
| Share price | $264.18 | $35.52 |
| Change, 1 year | 6.9% | 5.8% |
| Change, 5 years | −21.6% | −35.2% |
| Beta (5Y) | 0.69 | 0.71 |
| Employees | 1,689 | 1,420 |
| StockData Score | ||
| Total score | 6 | 15 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 5 (better) |
| Health score | 0 | 0 |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 41.1× | 22.6× (better) |
| P/S | 8.8× | 6.6× (better) |
| P/B | 3.2× (better) | 3.9× |
| EV/EBITDA | 13.8× | 9.5× (better) |
| PEG | 2.24 | 0.36 (better) |
| Fair value | $203.99 | $53.29 |
| Margin of safety | −29.5% | 33.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 4.7% (better) | 1.5% |
| Revenue growth, 5Y average | 4.8% | 6.6% (better) |
| Net income growth (TTM) | – | 296% |
| EPS growth (TTM) | −48.3% | 313% (better) |
| EPS growth, 5Y average | 3.7% | 41.4% (better) |
| Profitability | ||
| Gross margin | 70.1% | – |
| Operating margin | 32.5% | 40.8% (better) |
| Net margin | – | 30.4% |
| Return on equity | – | 16.7% |
| Return on invested capital | 9.1% | 22.3% (better) |
| Financial health | ||
| Interest coverage | 2.4× | 3.6× (better) |
| Altman Z-score | 1.69 (better) | 1.46 |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Dividend yield | 3.9% | 4.1% (better) |
| Payout ratio | – | 109% |
| Years of dividend growth | 9 | 16 (better) |
| Dividend growth, 5Y average | 4.3% (better) | 3.8% |
| Buyback yield | – | 3.7% |
| Shareholder yield | 3.9% | 7.7% (better) |
| Ownership | ||
| Held by institutions | 101% | 105% |
| Held by insiders | 0.73% | 0.47% |
| Insider net buying, 12 months | −$168K (better) | −$3.1M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.0% | 3.3% |
Go deeper
- ESS stock overview
- ESS income statement
- ESS valuation and score
- UDR stock overview
- UDR income statement
- UDR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.